{"id":"https://openalex.org/W2792006020","doi":"https://doi.org/10.1001/jamaoncol.2017.5236","title":"Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis","display_name":"Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis","alternate_titles":[],"publication_year":2018,"publication_date":"2018-02-22","ids":{"openalex":"https://openalex.org/W2792006020","doi":"https://doi.org/10.1001/jamaoncol.2017.5236","mag":"2792006020","pmid":"https://pubmed.ncbi.nlm.nih.gov/29470579","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5885200"},"language":"en","primary_location":{"id":"doi:10.1001/jamaoncol.2017.5236","doi":"https://doi.org/10.1001/jamaoncol.2017.5236","is_oa":true,"landing_page_url":"https://doi.org/10.1001/jamaoncol.2017.5236","pdf_url":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2673078/jamaoncology_ritchie_2018_oi_170096.pdf","source":{"id":"https://openalex.org/S2756165422","display_name":"JAMA Oncology","issn_l":"2374-2437","issn":["2374-2437","2374-2445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2792006020"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2673078/jamaoncology_ritchie_2018_oi_170096.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111644641","display_name":"Georgia E. Ritchie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I31746571","display_name":"UNSW Sydney","ror":"https://ror.org/03r8z3t63","country_code":"AU","type":"education","lineage":["https://openalex.org/I31746571"]},{"id":"https://openalex.org/I4210123059","display_name":"St George Hospital","ror":"https://ror.org/02pk13h45","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210123059"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Georgia Ritchie","raw_affiliation_strings":["Cancer Care Centre, St George Hospital, Sydney, Australia","School of Medicine, University of New South Wales, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Centre, St George Hospital, Sydney, Australia","institution_ids":["https://openalex.org/I4210123059"]},{"raw_affiliation_string":"School of Medicine, University of New South Wales, Sydney, Australia","institution_ids":["https://openalex.org/I31746571"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035619061","display_name":"Harry Michael Gasper","orcid":"https://orcid.org/0000-0003-0290-5762","observed_orcids":["https://orcid.org/0000-0003-0290-5762"]},"institutions":[{"id":"https://openalex.org/I4210123059","display_name":"St George Hospital","ror":"https://ror.org/02pk13h45","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210123059"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Harry Gasper","raw_affiliation_strings":["Cancer Care Centre, St George Hospital, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Centre, St George Hospital, Sydney, Australia","institution_ids":["https://openalex.org/I4210123059"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059121058","display_name":"Johnathan Man","orcid":"https://orcid.org/0000-0002-8505-1506","observed_orcids":["https://orcid.org/0000-0002-8505-1506"]},"institutions":[{"id":"https://openalex.org/I4210123059","display_name":"St George Hospital","ror":"https://ror.org/02pk13h45","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210123059"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Johnathan Man","raw_affiliation_strings":["Cancer Care Centre, St George Hospital, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Centre, St George Hospital, Sydney, Australia","institution_ids":["https://openalex.org/I4210123059"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052465499","display_name":"Sarah J. Lord","orcid":"https://orcid.org/0000-0003-2763-5949","observed_orcids":["https://orcid.org/0000-0003-2763-5949"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I42131985","display_name":"National Health and Medical Research Council","ror":"https://ror.org/011kf5r70","country_code":"AU","type":"government","lineage":["https://openalex.org/I2801453606","https://openalex.org/I3149551504","https://openalex.org/I42131985"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sally Lord","raw_affiliation_strings":["National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia","School of Medicine, University of Notre Dame, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I42131985"]},{"raw_affiliation_string":"School of Medicine, University of Notre Dame, Sydney, Australia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003569285","display_name":"Ian C. Marschner","orcid":"https://orcid.org/0000-0002-6225-1572","observed_orcids":["https://orcid.org/0000-0002-6225-1572"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I42131985","display_name":"National Health and Medical Research Council","ror":"https://ror.org/011kf5r70","country_code":"AU","type":"government","lineage":["https://openalex.org/I2801453606","https://openalex.org/I3149551504","https://openalex.org/I42131985"]},{"id":"https://openalex.org/I99043593","display_name":"Macquarie University","ror":"https://ror.org/01sf06y89","country_code":"AU","type":"education","lineage":["https://openalex.org/I99043593"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ian Marschner","raw_affiliation_strings":["Department of Statistics, Macquarie University, Sydney, Australia","National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Statistics, Macquarie University, Sydney, Australia","institution_ids":["https://openalex.org/I99043593"]},{"raw_affiliation_string":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I42131985"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021894535","display_name":"Michael Leonard Friedlander","orcid":"https://orcid.org/0000-0003-3090-795X","observed_orcids":["https://orcid.org/0000-0003-3090-795X"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I31746571","display_name":"UNSW Sydney","ror":"https://ror.org/03r8z3t63","country_code":"AU","type":"education","lineage":["https://openalex.org/I31746571"]},{"id":"https://openalex.org/I4210108821","display_name":"Prince of Wales Hospital","ror":"https://ror.org/022arq532","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210108821"]},{"id":"https://openalex.org/I42131985","display_name":"National Health and Medical Research Council","ror":"https://ror.org/011kf5r70","country_code":"AU","type":"government","lineage":["https://openalex.org/I2801453606","https://openalex.org/I3149551504","https://openalex.org/I42131985"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael Friedlander","raw_affiliation_strings":["National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia","Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, Australia","School of Medicine, University of New South Wales, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I42131985"]},{"raw_affiliation_string":"Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, Australia","institution_ids":["https://openalex.org/I4210108821"]},{"raw_affiliation_string":"School of Medicine, University of New South Wales, Sydney, Australia","institution_ids":["https://openalex.org/I31746571"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071066396","display_name":"Chee Khoon Lee","orcid":"https://orcid.org/0000-0003-2955-9820","observed_orcids":["https://orcid.org/0000-0003-2955-9820"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I4210123059","display_name":"St George Hospital","ror":"https://ror.org/02pk13h45","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210123059"]},{"id":"https://openalex.org/I42131985","display_name":"National Health and Medical Research Council","ror":"https://ror.org/011kf5r70","country_code":"AU","type":"government","lineage":["https://openalex.org/I2801453606","https://openalex.org/I3149551504","https://openalex.org/I42131985"]}],"countries":["AU"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Chee Khoon Lee","raw_affiliation_strings":["Cancer Care Centre, St George Hospital, Sydney, Australia","National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Centre, St George Hospital, Sydney, Australia","institution_ids":["https://openalex.org/I4210123059"]},{"raw_affiliation_string":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I42131985"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5071066396"],"corresponding_institution_ids":["https://openalex.org/I129604602","https://openalex.org/I4210123059","https://openalex.org/I42131985"],"apc_list":null,"apc_paid":null,"fwci":1.4979,"has_fulltext":true,"cited_by_count":126,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.83996248,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"4","issue":"4","first_page":"522","last_page":"522"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.7515000104904175,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.7515000104904175,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.23229999840259552,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.984000027179718},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.972000002861023},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8809999823570251},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/surrogate-endpoints","display_name":"surrogate endpoints","score":0.7409999966621399},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8569999933242798},{"id":"https://openalex.org/keywords/trial-design","display_name":"trial design","score":0.3540000021457672},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.3190000057220459},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.49799999594688416},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6359999775886536}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8732304573059082},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6639239192008972},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6571812033653259},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.637319803237915},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.5958981513977051},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5754072070121765},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5071089267730713},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.5061723589897156},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.49214547872543335},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.41754329204559326},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3880773186683655},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.24719294905662537}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000302","qualifier_name":"isolation & purification","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D054316","descriptor_name":"Biomarkers, Pharmacological","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D059447","descriptor_name":"Cell Cycle Checkpoints","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D059447","descriptor_name":"Cell Cycle Checkpoints","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1001/jamaoncol.2017.5236","doi":"https://doi.org/10.1001/jamaoncol.2017.5236","is_oa":true,"landing_page_url":"https://doi.org/10.1001/jamaoncol.2017.5236","pdf_url":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2673078/jamaoncology_ritchie_2018_oi_170096.pdf","source":{"id":"https://openalex.org/S2756165422","display_name":"JAMA Oncology","issn_l":"2374-2437","issn":["2374-2437","2374-2445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Oncology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5367950","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5885200","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5885200","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5885200/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Oncol","raw_type":"Text"},{"id":"pmid:29470579","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29470579","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA oncology","raw_type":"Journal Article"},{"id":"pmh:oai:https://researchers.mq.edu.au:publications/424c4193-3c01-4756-8070-0d07c92cc0cb","doi":null,"is_oa":false,"landing_page_url":"https://www.scopus.com/pages/publications/85047481203","pdf_url":null,"source":{"id":"https://openalex.org/S7407050580","display_name":"Macquarie University","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I99043593","host_organization_name":"Macquarie University","host_organization_lineage":["https://openalex.org/I99043593"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ritchie, G, Gasper, H, Man, J, Lord, S, Marschner, I, Friedlander, M & Lee, C K 2018, 'Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers a systematic review and meta-analysis', JAMA Oncology, vol. 4, no. 4, pp. 522-528. https://doi.org/10.1001/jamaoncol.2017.5236","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1001/jamaoncol.2017.5236","doi":"https://doi.org/10.1001/jamaoncol.2017.5236","is_oa":true,"landing_page_url":"https://doi.org/10.1001/jamaoncol.2017.5236","pdf_url":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2673078/jamaoncology_ritchie_2018_oi_170096.pdf","source":{"id":"https://openalex.org/S2756165422","display_name":"JAMA Oncology","issn_l":"2374-2437","issn":["2374-2437","2374-2445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2792006020.pdf","grobid_xml":"https://content.openalex.org/works/W2792006020.grobid-xml"},"referenced_works_count":58,"referenced_works":["https://openalex.org/W1809627231","https://openalex.org/W1964597234","https://openalex.org/W1965494873","https://openalex.org/W2050085247","https://openalex.org/W2066671159","https://openalex.org/W2095826876","https://openalex.org/W2098414192","https://openalex.org/W2100158834","https://openalex.org/W2101571970","https://openalex.org/W2102722484","https://openalex.org/W2104347254","https://openalex.org/W2106511606","https://openalex.org/W2107120363","https://openalex.org/W2112121482","https://openalex.org/W2114747879","https://openalex.org/W2123363005","https://openalex.org/W2128035403","https://openalex.org/W2136746908","https://openalex.org/W2137614346","https://openalex.org/W2139248078","https://openalex.org/W2155189639","https://openalex.org/W2155599713","https://openalex.org/W2156353875","https://openalex.org/W2174280796","https://openalex.org/W2198093519","https://openalex.org/W2222086386","https://openalex.org/W2289712604","https://openalex.org/W2291203170","https://openalex.org/W2293531514","https://openalex.org/W2296049142","https://openalex.org/W2342104528","https://openalex.org/W2344400860","https://openalex.org/W2418354692","https://openalex.org/W2465249712","https://openalex.org/W2468576628","https://openalex.org/W2480201404","https://openalex.org/W2494992707","https://openalex.org/W2503552011","https://openalex.org/W2510686645","https://openalex.org/W2519279652","https://openalex.org/W2527905628","https://openalex.org/W2529484692","https://openalex.org/W2529904548","https://openalex.org/W2530516001","https://openalex.org/W2531934133","https://openalex.org/W2547330766","https://openalex.org/W2547680646","https://openalex.org/W2559804019","https://openalex.org/W2560367415","https://openalex.org/W2567564314","https://openalex.org/W2572174216","https://openalex.org/W2589804830","https://openalex.org/W2592144107","https://openalex.org/W2595956476","https://openalex.org/W2598203798","https://openalex.org/W2600223557","https://openalex.org/W2624791371","https://openalex.org/W2627045858"],"related_works":["https://openalex.org/W4379284041","https://openalex.org/W3186806797","https://openalex.org/W2762900847","https://openalex.org/W4417524673","https://openalex.org/W3084135554","https://openalex.org/W4407694297","https://openalex.org/W2765124300","https://openalex.org/W2979070604","https://openalex.org/W3036581059"],"abstract_inverted_index":{"IMPORTANCE:":[0],"Checkpoint":[1],"inhibitors":[2],"have":[3],"a":[4,24,315],"unique":[5],"mechanism":[6],"of":[7,18,44,59,86,168,177,217],"action":[8],"that":[9],"differs":[10],"from":[11,74,156],"chemotherapy":[12],"or":[13],"targeted":[14],"therapies.":[15],"The":[16],"validity":[17],"objective":[19],"response":[20],"rate":[21,362],"(ORR)":[22],"as":[23,365],"surrogate":[25],"for":[26,61,114,120,128],"progression-free":[27],"survival":[28,32],"(PFS)":[29],"and":[30,54,65,81,97,110,116,133,152,160,181,230,241,249,253,277,296,320,332],"overall":[31],"(OS)":[33],"in":[34,49,71,94,164],"checkpoint-inhibitor":[35,52,124,263,348],"trials":[36,188,203],"is":[37,363],"uncertain.":[38],"OBJECTIVE:":[39],"To":[40],"determine":[41],"the":[42,57,82,192,262,337],"types":[43],"primary":[45,197],"end":[46,198,367],"points":[47],"used":[48,308,327],"phase":[50,95,98,186,357],"2":[51,96,187,358],"trials,":[53,349],"to":[55,76,148,288,294,309,328],"assess":[56],"strength":[58],"associations":[60],"ORR":[62,107,129,157,178,190,216,227,238,269,273,325,350],"with":[63,130,179,204,214,270,274,280,353],"PFS":[64,115,132,151,180,231,251,279,306,331,361],"OS.":[66,182,323,354],"DATA":[67,101],"SOURCES:":[68],"Trials":[69],"listed":[70],"electronic":[72],"databases":[73],"2000":[75],"2017":[77],"(PREMEDLINE,":[78],"MEDLINE,":[79],"Embase,":[80],"Cochrane":[83],"Central":[84],"Register":[85],"Controlled":[87],"Trials).":[88],"STUDY":[89],"SELECTION:":[90],"Advanced":[91],"solid":[92],"cancers":[93],"3":[99],"trials.":[100,169],"EXTRACTION":[102],"AND":[103,172,345],"SYNTHESIS:":[104],"Correlations":[105],"between":[106,226,250,268,318],"odds":[108,228,239],"ratios":[109,112],"hazard":[111],"(HRs)":[113],"OS":[117,135,154,242,254,282,334],"were":[118,137,141,158,208,283],"examined":[119],"randomized":[121,201,223],"comparisons.":[122],"Within":[123,261],"treatment":[125,206],"arms,":[126,264],"correlations":[127],"6-month":[131,150,271,278,305,330,360],"12-month":[134,153,275,281,311,322,333],"rates":[136,155,341],"examined.":[138],"All":[139],"analyses":[140],"weighted":[142],"by":[143],"trial":[144],"size.":[145],"Multivariable":[146],"models":[147],"predict":[149,310,329],"developed":[159],"their":[161],"performance":[162],"validated":[163],"an":[165,366],"independent":[166],"sample":[167],"MAIN":[170],"OUTCOMES":[171],"MEASURES:":[173],"Correlation":[174],"coefficient":[175],"(r)":[176],"RESULTS:":[183],"Of":[184],"87":[185],"identified,":[189],"was":[191,212,233,244,256,307,314,326],"most":[193],"common":[194],"(52":[195],"[60%])":[196],"point.":[199,368],"Twenty":[200],"clinical":[202],"25":[205],"comparisons":[207],"identified.":[209],"Checkpoint-inhibitor":[210],"therapy":[211],"associated":[213],"pooled":[215],"24%":[218],"(95%":[219,235,246,258,285,291,298],"CI,":[220,236,247,259,286,292,299],"18%-31%).":[221],"For":[222,355],"comparisons,":[224],"r":[225,265],"ratio":[229,240],"HR":[232,243,252,255],"0.63":[234],"0.35-0.89),":[237],"0.57":[245],"0.23-0.89),":[248],"0.42":[257],"0.04-0.81).":[260],"correlation":[266],"coefficients":[267],"PFS,":[272],"OS,":[276,312],"0.37":[284],"-0.06":[287],"0.95),":[289],"0.08":[290],"-0.17":[293],"0.70),":[295],"0.74":[297],"0.57-0.92),":[300],"respectively.":[301],"In":[302,347],"validation,":[303],"when":[304],"there":[313],"good":[316],"calibration":[317],"actual":[319,338],"predicted":[321,340],"When":[324],"rates,":[335],"respectively,":[336],"vs":[339],"calibrated":[342],"poorly.":[343],"CONCLUSIONS":[344],"RELEVANCE:":[346],"correlated":[351],"poorly":[352],"future":[356],"studies,":[359],"recommended":[364]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2792006020","counts_by_year":[{"year":2026,"cited_by_count":11},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":13},{"year":2023,"cited_by_count":16},{"year":2022,"cited_by_count":24},{"year":2021,"cited_by_count":17},{"year":2020,"cited_by_count":18},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":6}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2018-03-29T00:00:00"}
